Adjuvant of the adapted diet, in diabetics with overweight

Oral use.

The dosage is usually 3 tablets per day. This dosage may be prescribed from the outset or attained progressively in the following manner:
· 1 st week: 1 tablet per day, during dinner

· 2 nd week: 2 tablets a day, 1 in the course of lunch, 1 during dinner

· From the 3rd week: 3 tablets per day, ie 1 at breakfast, 1 at lunch, 1 at dinner.
Depending on the results, the dosage may be decreased to 2 tablets per day, or even 1 tablet per day.
In combination with a suitable diet, BENFLUOREX QUALIMED is an adjuvant treatment, with regular clinical and biological monitoring of each patient.


ATC code A16X

Actions of BENFLUOREX QUALIMED on carbohydrate metabolism

In animals, the following effects have been observed:

- facilitating the penetration and cellular utilization of glucose (rat)

- decrease in hyperglycemia in diabetic rats (insulinoprive or not), decrease in hyperglycemia (measured by the area of ​​HPO) in rabbits

BENFLUOREX QUALIMED has no action on insulin secretion, onset, hypoglycemia is unlikely.

The attention of drivers is drawn to the drowsiness that may occur when using this medication.
· Hypersensitivity to benfluorex hydrochloride or to any of the constituents

· Chronic chronic pancreatitis.

The metabolic disorders under treatment with BENFLUOREX QUALIMED are mainly observed in adults. The prescription of BENFLUOREX QUALIMED is therefore not justified in children.

If, after a period of administration of a few months (3 to 6 months), a satisfactory reduction in serum glucose concentrations is not obtained, complementary or different therapeutic means should be considered.

The attention of sportsmen and sportswomen will be drawn to the fact that this specialty contains an active ingredient which can induce a positive reaction of the tests performed during the antidoping tests. Code>
Because of the presence of sucrose, this drug is contraindicated in patients with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency (rare hereditary diseases).

Without object.

Not applicable.

In case of massive absorption, the treatment will only be symptomatic: gastric lavage, diuresis, osmotic, correction of electrolyte disturbances, monitoring of blood pressure, consciousness as well as respiratory function and; Heart.


Studies in animals have not shown any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been found to be teratogenic in animals in well-conducted studies of two species

In clinical terms, there is currently no adequate data to assess a possible malformative or fetotoxic effect of benfluorex when administered during pregnancy.
Therefore, as a precaution, it is preferable not to use this drug during pregnancy. In case of accidental exposure, this treatment should be discontinued.


In the absence of data on the passage of benfluorex in breast milk, this medication is not recommended during breast-feeding.
The following side effects have been observed

· Digestive problems (nausea, vomiting, gastralgia, diarrhea), asthenia, somnolence or dizziness. However, they are observed more particularly at doses greater than 3 tablets per day and vary according to the individual susceptibilities

· Very rare cases of anaphylactic reactions, hypotension, shock, skin rash, urticaria, edema of Quicke

· Elevation of liver enzymes, hepatitis (very rare).

Confusion, disorders of cognitive functions, temporal-spatial disorientation, behavioral disorders: agitation, delirium, disorders of hallucination (very rare). Code>
Adjuvant of the adapted diet, in diabetics with overweight